Research and Markets (http://www.researchandmarkets.com/research/391d8eeb/japan_pharmaceutic) has announced the addition of the "Japan Pharmaceuticals and Healthcare Report Q2 2012" report to their offering.
Japan's pharmaceutical market is highly attractive to both foreign and local drugmakers. All three sub-sectors - patented, generic and over-the-counter (OTC) medicines - are large and forecast to growth over the medium term. Regulations are well-developed, transparent and improving. The key risk to this outlook is economic fragility and political uncertainty.
BMI's forecast has been revised down from Q112 due to the receipt of new historic data.
Key Trends And Developments:
- In January 2012, Takeda said it will cut its workforce by 9% by March 31 2016. The company will make most of the 2,800 redundancies in Europe and the US as it attempts to save US$1.7bn through the integration of US$12bn Swiss acquisition Nycomed.
- In December 2011, Indian pharmaceutical company Elder Pharmaceutical announced plans to enter the Japanese pharmaceutical market during FY12, having gained Japanese Ministry of Health accreditation for its facility in Patalganga, India.
- In November 2011, Asahi Kasei Pharma said it will establish a new research complex in its Pharmaceuticals Research Centre in Shizuoka. The company will install advanced experimental apparatus and facilities at the new complex, which it said will ensure higher functionality and efficiency to carry out research with more competitive superiority.
ABOUT THIS REPORT
Business Monitor International's Japan Pharmaceuticals and Healthcare Report provides industry professionals and strategists, corporate analysts, pharmaceutical associations, government departments and regulatory bodies with independent forecasts and competitive intelligence on Japan's pharmaceuticals and healthcare industry.
Key Topics Covered:
- Executive Summary
- SWOT Analysis
- Japan - Market Summary
- Industry Forecast Scenario
- Competitive Landscape
- Company Profiles
- Country Snapshot: Japan Demographic Data
- Glossary
- BMI Methodology
Companies Mentioned
- Takeda Pharmaceutical Company
- Astellas
- Eisai
- Daiichi Sankyo
- Mitsubishi Tanabe
- Sawai Pharmaceutical
- Pfizer
- Sanofi
- Merck & Co (Banyu)
- Novartis
- GlaxoSmithKline
- AstraZeneca
For more information, including full table of contents, please visit http://www.researchandmarkets.com/research/391d8eeb/japan_pharmaceutic